A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)	B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 2	2026-09-30		NCT07231952

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AbbVie	340
Eli Lilly and Company	370
Memorial Sloan Kettering Cancer Center	753

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center (Data Collection Only)	Boston	United States	2
Dana Farber Cancer Institute (Data Collection and Specimen Analysis)	Boston	United States	3
Memoral Sloan Kettering Monmouth	Middletown	United States	1
Memorial Sloan Kettering Basking Ridge	Basking Ridge	United States	189
Memorial Sloan Kettering Bergen	Montvale	United States	193
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Memorial Sloan Kettering Nassau	Uniondale	United States	193
Memorial Sloan Kettering Suffolk - Commack	Commack	United States	6
Memorial Sloan Kettering Westchester	Harrison	United States	204